Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VISION: Fluorescent Vedolizumab Imaging in IBD
NCT04112212Phase 1Completed
- Sponsor
- University Medical Center Groningen
- Start
- Nov 2020
- Primary completion
- Oct 2022
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of vedolizumab in Crohn's disease and ulcerative colitis (UC) (6 arms), sponsored by University Medical Center Groningen. Primary endpoint: Fluorescent signal in patients with IBD at 18 months. Started Nov 2020; status: completed.
02
Drugs
vedolizumab
03
Conditions
Crohn's diseaseulcerative colitis (UC)
Beyond the preview
Go deeper on NCT04112212.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04112212.